🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with high-risk biochemically recurrent prostate cancer following prostatectomy. ja.ma/3SXsCLu

Dr. Benjamin Teply from University of Nebraska Medical Center delivers an engaging presentation on the efficacy and safety outcomes of an open-label trial with olaparib monotherapy in high-risk biochemically recurrent prostate cancer. #DAVAGU

Optimizing bone health in hormone-sensitive prostate cancer (w/o bone metastases) is crucial! Insights from Dr. Benjamin Teply from @UNMC on balancing treatment & bone preservation. #ProstateCancer #BoneHealth #DAVAGU